SynthesisFrontiers in pharmacology2023
Neuroprotective effects and possible mechanisms of berberine in animal models of Alzheimer's disease: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Unlocking the healing power of Berberine: A promising aid for multiple sclerosis.IBRO neuroscience reports · 2026Review
- Berberine Impedes Acute Pancreatitis Development by Suppressing VNN1 Expression and the NF-κB Signaling Pathway.Molecular biotechnology · 2026Article
- Emerging roles of combined curcumin and berberine in disease modulation: a comprehensive review of mechanisms and therapeutic relevance.Molecular biology reports · 2026Review
- Berberine enhances cisplatin efficacy in ehrlich ascites carcinoma via modulation of apoptotic pathway and efferocytosis.Scientific reports · 2026Article
- Artificial intelligence and machine learning for precision prevention of cognitive decline: integrating multimodal biomarkers, lifestyle interventions, and natural medicines from prediction to clinical practice.Frontiers in aging neuroscience · 2026Review
- Nanomedicine-enabled neuroprotection: therapeutic role of berberine in neurodegenerative diseases.Molecular biology reports · 2025Review
- From Liquid SNEDDS to Solid SNEDDS: A Comprehensive Review of Their Development and Pharmaceutical Applications.The AAPS journal · 2025Review
- From metabolic dysregulation to neurodegenerative pathology: the role of hyperglycemia, oxidative stress, and blood-brain barrier breakdown in T2D-driven Alzheimer's disease.Metabolic brain disease · 2025Review
- Nanoparticles as an Encouraging Therapeutic Approach to Alzheimer's Disease.International journal of molecular sciences · 2025Review
- Review
- Network pharmacology study on the mechanism of berberine in Alzheimer's disease model.NPJ science of food · 2025Article
- Integrated Colorisensing Platform with Microneedles and Metal-Phenol Nanozymes for Point-of-Care Testings of Acetylcholinesterase Activity and Its Drug Inhibitor.International journal of nanomedicine · 2025Article
- Recent Advancements in Lipid Nanoparticles-Based Phytoactives Delivery Systems for Neurodegenerative Diseases.International journal of nanomedicine · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.